Clinical Scorecard: CGM Shows Potential for Diagnosing Diabetes in Pregnancy
At a Glance
| Category | Detail |
|---|---|
| Condition | Gestational Diabetes Mellitus (GDM) |
| Key Mechanisms | Continuous glucose monitoring (CGM) metrics such as mean glucose, glycemic variability, and time in glucose ranges. |
| Target Population | Pregnant patients at risk for GDM. |
| Care Setting | Obstetric care settings. |
Key Highlights
- CGM metrics can differentiate patients who develop GDM from those who do not.
- Higher mean glucose and greater variability observed as early as 13-14 weeks gestation.
- CGM-derived patterns correlate with adverse neonatal outcomes.
- Current evidence does not support CGM as a replacement for OGTT.
- Future diagnostic criteria for CGM may need to be device specific.
Guideline-Based Recommendations
Diagnosis
- CGM may complement existing screening strategies but is not validated as a standalone diagnostic test.
Management
- CGM used alongside pharmacotherapy may reduce rates of large-for-gestational-age births.
Monitoring & Follow-up
- Monitor CGM metrics for glycemic control in pregnant patients.
Risks
- Adverse neonatal outcomes associated with prolonged time above target glucose levels.
Patient & Prescribing Data
Pregnant individuals at risk for gestational diabetes.
Mixed findings on the effectiveness of CGM for managing GDM.
Clinical Best Practices
- Utilize CGM data to inform management strategies for GDM.
- Consider CGM as a supplementary tool rather than a replacement for OGTT.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
